Zevra Therapeutics Announces Final CHMP Opinion on Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union
European Commission to make final decision on arimoclomol MAA following negative CHMP opinion European Commission to make final decision on arimoclomol MAA following negative CHMP opinion